Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03399513
Title Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Muenster
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Ibrutinib + Prednisolone + Rituximab + Vincristine Sulfate

Age Groups: adult
Covered Countries DEU


No variant requirements are available.